Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX’s action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kciuk, Mateusz, Gielecińska, Adrianna, Mujwar, Somdutt, Kołat, Damian, Kałuzińska-Kołat, Żaneta, Celik, Ismail, Kontek, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954613/
https://www.ncbi.nlm.nih.gov/pubmed/36831326
http://dx.doi.org/10.3390/cells12040659
_version_ 1784894160419946496
author Kciuk, Mateusz
Gielecińska, Adrianna
Mujwar, Somdutt
Kołat, Damian
Kałuzińska-Kołat, Żaneta
Celik, Ismail
Kontek, Renata
author_facet Kciuk, Mateusz
Gielecińska, Adrianna
Mujwar, Somdutt
Kołat, Damian
Kałuzińska-Kołat, Żaneta
Celik, Ismail
Kontek, Renata
author_sort Kciuk, Mateusz
collection PubMed
description Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX’s action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.
format Online
Article
Text
id pubmed-9954613
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99546132023-02-25 Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity Kciuk, Mateusz Gielecińska, Adrianna Mujwar, Somdutt Kołat, Damian Kałuzińska-Kołat, Żaneta Celik, Ismail Kontek, Renata Cells Review Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX’s action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy. MDPI 2023-02-19 /pmc/articles/PMC9954613/ /pubmed/36831326 http://dx.doi.org/10.3390/cells12040659 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kciuk, Mateusz
Gielecińska, Adrianna
Mujwar, Somdutt
Kołat, Damian
Kałuzińska-Kołat, Żaneta
Celik, Ismail
Kontek, Renata
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
title Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
title_full Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
title_fullStr Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
title_full_unstemmed Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
title_short Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
title_sort doxorubicin—an agent with multiple mechanisms of anticancer activity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954613/
https://www.ncbi.nlm.nih.gov/pubmed/36831326
http://dx.doi.org/10.3390/cells12040659
work_keys_str_mv AT kciukmateusz doxorubicinanagentwithmultiplemechanismsofanticanceractivity
AT gielecinskaadrianna doxorubicinanagentwithmultiplemechanismsofanticanceractivity
AT mujwarsomdutt doxorubicinanagentwithmultiplemechanismsofanticanceractivity
AT kołatdamian doxorubicinanagentwithmultiplemechanismsofanticanceractivity
AT kałuzinskakołatzaneta doxorubicinanagentwithmultiplemechanismsofanticanceractivity
AT celikismail doxorubicinanagentwithmultiplemechanismsofanticanceractivity
AT kontekrenata doxorubicinanagentwithmultiplemechanismsofanticanceractivity

Ejemplares similares